Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Actemra®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
February 14, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022